Seeking Alpha

Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron...

Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron Research. Citron is saying that Aetna (AET -0.5%) has dropped almost all coverage of QCOR's drug Achtar for treating multiple sclerosis and nephrotic symdrome, saying that studies found no proof of efficacy to substantiate reimbursement. It will, however, continue to provide reimbursement when treating infantile spasms.
Comments (4)
  • And thus Aetna declares their bean counters are better at evaluating clinical data than is the FDA. Looks to me that there will be a paper fusillade of such declarations from Aetna as they "justify" MANY treatment denials to boost their meager profit margins. Nice!
    19 Sep 2012, 11:22 AM Reply Like
  • Aetna is practicing evidence based medicine (EBM)--- For the treatment of MS relapses and nephrotic syndrome, ACTH is no better than IV methylprednisolone which is a fraction of the cost. Why should they pay $24000 more for the same effect?

     

    On the other hand, EBM favors ACTH for Infantile spasms (West Syndrome) over vigabatrin and Aetna is agreeing to cover it for that true orphan indication.
    19 Sep 2012, 08:46 PM Reply Like
  • I wonder how many people followed Oppenheimer yesterday when it upped the price target on this stock to 69.00 from 59.00. Hahaha.
    19 Sep 2012, 11:28 AM Reply Like
  • Insurance companies for profit is the problem. They dictate what a person takes based on bottom line profits not whats best for the patient. A true conflict of interest!
    23 Sep 2012, 07:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)